Yadav S, Gandhi V, Yadav P. Oral Involvement in Borderline Tuberculoid Leprosy: Report of a Case with Review of Literature. Indian Dermatol Online J. 2023 May-Jun. 14 (3):388-390. [QxMD MEDLINE Link]. [Full Text].
Galeano J, Contreras A, Pabón L, et al. Case Report: Necrotizing Erythema Nodosum as a Manifestation of Lepromatous Leprosy Relapse 50 Years after the Initial Infection. Am J Trop Med Hyg. 2023 May 30. [QxMD MEDLINE Link].
Khambati FA, Shetty VP, Ghate SD, Capadia GD. Sensitivity and specificity of nerve palpation, monofilament testing and voluntary muscle testing in detecting peripheral nerve abnormality, using nerve conduction studies as gold standard; a study in 357 patients. Lepr Rev. 2009 Mar. 80(1):34-50. [QxMD MEDLINE Link].
Rao PN, Jain S. Newer management options in leprosy. Indian J Dermatol. 2013 Jan. 58(1):6-11. [QxMD MEDLINE Link]. [Full Text].
Bhushan P, Sardana K, Koranne RV, Choudhary M, Manjul P. Diagnosing multibacillary leprosy: a comparative evaluation of diagnostic accuracy of slit-skin smear, bacterial index of granuloma and WHO operational classification. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug. 74(4):322-6. [QxMD MEDLINE Link].
Garbino JA, Marques W Jr, Barreto JA, Heise CO, Rodrigues MM, Antunes SL, et al. Primary neural leprosy: systematic review. Arq Neuropsiquiatr. 2013 Jun. 71(6):397-404. [QxMD MEDLINE Link].
World Health Organization. WHO-recommended MDT regimens. World Health Organization. Available at http://www.who.int/lep/mdt/MDT_Regimens.pdf?ua=1.
Jing Z, Zhang R, Zhou D, Chen J. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy. Lepr Rev. 2009 Jun. 80(2):170-6. [QxMD MEDLINE Link].
Han XY, Sizer KC, Thompson EJ, Kabanja J, Li J, Hu P, et al. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol. 2009 Oct. 191(19):6067-74. [QxMD MEDLINE Link]. [Full Text].
Neglected tropical diseases. World Health Organization. Available at http://www.who.int/neglected_diseases/diseases/en/. 2018; Accessed: May 14, 2018.
Global leprosy update, 2016: accelerating reduction of disease burden. Wkly Epidemiol Rec. 2017 Sep 1. 92 (35):501-19. [QxMD MEDLINE Link].
Truman RW, Singh P, Sharma R, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011 Apr 28. 364(17):1626-33. [QxMD MEDLINE Link].
Masaki T, Qu J, Cholewa-Waclaw J, Burr K, Raaum R, Rambukkana A. Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection. Cell. 2013 Jan 17. 152(1-2):51-67. [QxMD MEDLINE Link].
Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis. 2013 Oct. 26(5):413-9. [QxMD MEDLINE Link].
Silva CAM, Belisle JT. Host Lipid Mediators in Leprosy: The Hypothesized Contributions to Pathogenesis. Front Immunol. 2018. 9:134. [QxMD MEDLINE Link].
McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol. 2005 Jul. 125(1):1-8. [QxMD MEDLINE Link].
Tapinos N, Ohnishi M, Rambukkana A. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med. 2006 Aug. 12(8):961-6. [QxMD MEDLINE Link].
Makino M, Maeda Y, Mukai T, Kaufmann SH. Impaired maturation and function of dendritic cells by mycobacteria through IL-1beta. Eur J Immunol. 2006 Jun. 36(6):1443-52. [QxMD MEDLINE Link].
Fulco TO, Lopes UG, Sarno EN, Sampaio EP, Saliba AM. The proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion. Immunol Lett. 2007 May 15. 110(1):82-5. [QxMD MEDLINE Link].
Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science. 2013 Mar 22. 339(6126):1448-53. [QxMD MEDLINE Link]. [Full Text].
Liu PT, Wheelwright M, Teles R, Komisopoulou E, Edfeldt K, Ferguson B. MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med. 2012 Feb. 18(2):267-73. [QxMD MEDLINE Link].
Goulart LR, Goulart IM. Leprosy pathogenetic background: a review and lessons from other mycobacterial diseases. Arch Dermatol Res. 2009 Feb. 301(2):123-37. [QxMD MEDLINE Link].
Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med. 2009 Dec 31. 361(27):2609-18. [QxMD MEDLINE Link].
Negera E, Bobosha K, Walker SL, Endale B, Howe R, Aseffa A, et al. New Insight into the Pathogenesis of Erythema Nodosum Leprosum: The Role of Activated Memory T-Cells. Front Immunol. 2017. 8:1149. [QxMD MEDLINE Link].
Pesce C, Grattarola M, Menini S, Fiallo P. Cyclooxygenase 2 expression in vessels and nerves in reversal reaction leprosy. Am J Trop Med Hyg. 2006 Jun. 74(6):1076-7. [QxMD MEDLINE Link].
Negera E, Walker SL, Bobosha K, Bekele Y, Endale B, Tarekegn A, et al. The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions. Front Immunol. 2018. 9:189. [QxMD MEDLINE Link].
Chaitanya VS, Lavania M, Nigam A, Turankar RP, Singh I, Horo I. Cortisol and proinflammatory cytokine profiles in type 1 (reversal) reactions of leprosy. Immunol Lett. 2013 Nov-Dec. 156(1-2):159-67. [QxMD MEDLINE Link].
Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol Leprol. 2013 Nov-Dec. 79(6):739-49. [QxMD MEDLINE Link].
Naves Mde M, Ribeiro FA, Patrocinio LG, Patrocinio JA, Fleury RN, Goulart IM. Bacterial load in the nose and its correlation to the immune response in leprosy patients. Lepr Rev. 2013 Mar. 84(1):85-91. [QxMD MEDLINE Link].
Morgado de Abreu MA, Roselino AM, Enokihara M, Nonogaki S, Prestes-Carneiro LE, Weckx LL. Mycobacterium leprae is identified in the oral mucosa from paucibacillary and multibacillary leprosy patients. Clin Microbiol Infect. 2014 Jan. 20(1):59-64. [QxMD MEDLINE Link].
Batista MD, Porro AM, Maeda SM, et al. Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS. Clin Infect Dis. 2008 Mar 15. 46(6):e56-60. [QxMD MEDLINE Link].
Menezes VM, Sales AM, Illarramendi X, et al. Leprosy reaction as a manifestation of immune reconstitution inflammatory syndrome: a case series of a Brazilian cohort. AIDS. 2009 Mar 13. 23(5):641-3. [QxMD MEDLINE Link].
Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis. 2006 Jul 15. 43(2):e19-22. [QxMD MEDLINE Link].
Camacho ID, Valencia I, Rivas MP, Burdick AE. Type 1 leprosy reaction manifesting after discontinuation of adalimumab therapy. Arch Dermatol. 2009 Mar. 145(3):349-51. [QxMD MEDLINE Link].
Ghorpade A. Ornamental tattoos and skin lesions. Tattoo inoculation borderline tuberculoid leprosy. Int J Dermatol. 2009 Jan. 48(1):11-3. [QxMD MEDLINE Link].
Trindade MA, Palermo ML, Pagliari C, et al. Leprosy in transplant recipients: report of a case after liver transplantation and review of the literature. Transpl Infect Dis. 2011 Feb. 13(1):63-9. [QxMD MEDLINE Link].
Ardalan M, Ghaffari A, Ghabili K, Shoja MM. Lepromatous leprosy in a kidney transplant recipient: a case report. Exp Clin Transplant. 2011 Jun. 9(3):203-6. [QxMD MEDLINE Link].
Vanderborght PR, Pacheco AG, Moraes ME, et al. HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun. 2007 Jun. 8(4):320-4. [QxMD MEDLINE Link].
Jarduli LR, Sell AM, Reis PG, Sippert EÂ, Ayo CM, Mazini PS. Role of HLA, KIR, MICA, and cytokines genes in leprosy. Biomed Res Int. 2013. 2013:989837. [QxMD MEDLINE Link].
Alter A, Alcaïs A, Abel L, Schurr E. Leprosy as a genetic model for susceptibility to common infectious diseases. Hum Genet. 2008 Apr. 123(3):227-35. [QxMD MEDLINE Link].
Schurr E, Alcaïs A, de Leseleuc L, Abel L. Genetic predisposition to leprosy: A major gene reveals novel pathways of immunity to Mycobacterium leprae. Semin Immunol. 2006 Dec. 18(6):404-10. [QxMD MEDLINE Link].
Goulart LR, Ferreira FR, Goulart IM. Interaction of TaqI polymorphism at exon 9 of the vitamin D receptor gene with the negative lepromin response may favor the occurrence of leprosy. FEMS Immunol Med Microbiol. 2006 Oct. 48(1):91-8. [QxMD MEDLINE Link].
Velayati AA, Farnia P, Khalizadeh S, Farahbod AM, Hasanzadh M, Sheikolslam MF. Interferon-gamma receptor-1 gene promoter polymorphisms and susceptibility to leprosy in children of a single family. Am J Trop Med Hyg. 2011 Apr. 84(4):627-9. [QxMD MEDLINE Link]. [Full Text].
Fava V, Orlova M, Cobat A, Alcaïs A, Mira M, Schurr E. Genetics of leprosy reactions: an overview. Mem Inst Oswaldo Cruz. 2012 Dec. 107 Suppl 1:132-42. [QxMD MEDLINE Link].
Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013 Aug 30. 88(35):365-79. [QxMD MEDLINE Link].
Salgado CG, Barreto JG, da Silva MB, Goulart IMB, Barreto JA, de Medeiros Junior NF, et al. Are leprosy case numbers reliable?. Lancet Infect Dis. 2018 Feb. 18 (2):135-137. [QxMD MEDLINE Link].
Drug resistance in leprosy: reports from selected endemic countries. Wkly Epidemiol Rec. 2009 Jun 26. 84(26):264-7. [QxMD MEDLINE Link].
Ludwig RJ, Henke U, Wolter M, et al. Persistence of peri-neural granulomas after successful treatment of leprosy. J Eur Acad Dermatol Venereol. 2007 Nov. 21(10):1414-6. [QxMD MEDLINE Link].
Cruz RCDS, Bührer-Sékula S, Penna MLF, Penna GO, Talhari S. Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients. An Bras Dermatol. 2017 Nov-Dec. 92 (6):761-773. [QxMD MEDLINE Link].
Gupta R, Kar HK, Bharadwaj M. Revalidation of various clinical criteria for the classification of leprosy--a clinic-pathological study. Lepr Rev. 2012 Dec. 83(4):354-62. [QxMD MEDLINE Link].
Bhat R, Sharma VK, Deka RC. Otorhinolaryngologic manifestations of leprosy. Int J Dermatol. 2007 Jun. 46(6):600-6. [QxMD MEDLINE Link].
Motta AC, Komesu MC, Silva CH, et al. Leprosy-specific oral lesions: a report of three cases. Med Oral Patol Oral Cir Bucal. 2008 Aug 1. 13(8):E479-82. [QxMD MEDLINE Link].
Sehgal VN, Srivastava G, Singh N, Prasad PV. Histoid leprosy: the impact of the entity on the postglobal leprosy elimination era. Int J Dermatol. 2009 Jun. 48(6):603-10. [QxMD MEDLINE Link].
Nascimento OJ. Leprosy neuropathy: clinical presentations. Arq Neuropsiquiatr. 2013 Sep. 71(9B):661-6. [QxMD MEDLINE Link].
Rai D, Malhotra HS, Garg RK, Goel MM, Malhotra KP, Kumar V, et al. Nerve abscess in primary neuritic leprosy. Lepr Rev. 2013 Jun. 84(2):136-40. [QxMD MEDLINE Link].
Antunes DE, Araujo S, Ferreira GP, Cunha AC, Costa AV, Gonçalves MA. Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy. Mem Inst Oswaldo Cruz. 2013 Nov. 108(7):901-8. [QxMD MEDLINE Link].
Rao PS, Sugamaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev. 2006 Mar. 77(1):25-33. [QxMD MEDLINE Link].
Safa G, Darrieux L, Coic A, Tisseau L. Type 1 leprosy reversal reaction treated with topical tacrolimus along with systemic corticosteroids. Indian J Med Sci. 2009 Aug. 63(8):359-62. [QxMD MEDLINE Link].
Aires NB, Refkalefsky Loureiro W, Villela MA, Sakai Valente NY, Trindade MA. Sweet's syndrome type leprosy reaction. J Eur Acad Dermatol Venereol. 2009 Apr. 23(4):467-9. [QxMD MEDLINE Link].
Chauhan S, D'Cruz S, Mohan H, Singh R, Ram J, Sachdev A. Type II lepra reaction: an unusual presentation. Dermatol Online J. 2006 Jan 27. 12(1):18. [QxMD MEDLINE Link].
Fabi SG, Hill C, Witherspoon JN, Boone SL, West DP. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. J Drugs Dermatol. 2009 Aug. 8(8):765-9. [QxMD MEDLINE Link].
Verma KK, Srivastava P, Minz A, Verma K. Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum. Lepr Rev. 2006 Sep. 77(3):225-9. [QxMD MEDLINE Link].
Kar BR, Babu R. Methotrexate in resistant ENL. Int J Lepr Other Mycobact Dis. 2004 Dec. 72(4):480-2. [QxMD MEDLINE Link].
Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. 2006 Aug 17. 355(7):739. [QxMD MEDLINE Link].
Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis. 2011 Mar 1. 52(5):e133-5. [QxMD MEDLINE Link].
Costa IM, Kawano LB, Pereira CP, Nogueira LS. Lucio's phenomenon: a case report and review of the literature. Int J Dermatol. 2005 Jul. 44(7):566-71. [QxMD MEDLINE Link].
Crawford CL. No role for thalidomide in the treatment of leprosy. J Infect Dis. 2006 Jun 15. 193(12):1743-4; author reply 1744-5. [QxMD MEDLINE Link].
Nery JA, Bernardes Filho F, Quintanilha J, Machado AM, Oliveira Sde S, Sales AM. Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol. 2013 Sep-Oct. 88(5):787-92. [QxMD MEDLINE Link].
Sahay G, Kar HK, Gupta R. Effect of Steroid Prophylaxis on Nerve Function Impairment in Multi-bacillary Leprosy Patients on MDT-MB. Indian J Lepr. 2015 Jul-Sep. 87 (3):133-43. [QxMD MEDLINE Link].
Bilodeau M, Burns S, Gawoski J, Moschella S, Ooi W. Co-morbid infections in Hansen's disease patients in the United States: considerations for treatment. Am J Trop Med Hyg. 2013 Oct. 89(4):781-3. [QxMD MEDLINE Link].
Sena CB, Salgado CG, Tavares CM, Da Cruz CA, Xavier MB, Do Nascimento JL. Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor. Lepr Rev. 2006 Jun. 77(2):121-9. [QxMD MEDLINE Link].
Nashed SG, Rageh TA, Attallah-Wasif ES, Abd-Elsayed AA. Intraneural injection of corticosteroids to treat nerve damage in leprosy: a case report and review of literature. J Med Case Reports. 2008 Dec 9. 2:381. [QxMD MEDLINE Link]. [Full Text].
Rath S, Schreuders TA, Selles RW. Early postoperative active mobilisation versus immobilisation following tibialis posterior tendon transfer for foot-drop correction in patients with Hansen's disease. J Plast Reconstr Aesthet Surg. 2009 Feb 19. [QxMD MEDLINE Link].
Shah RK. Tibialis posterior transfer by interosseous route for the correction of foot drop in leprosy. Int Orthop. 2009 Dec. 33(6):1637-40. [QxMD MEDLINE Link].
Kanaji A, Higashi M, Namisato M, Nishio M, Ando K, Yamada H. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Lepr Rev. 2006 Jun. 77(2):147-53. [QxMD MEDLINE Link].
Pereira HL, Ribeiro SL, Pennini SN, Sato EI. Leprosy-related joint involvement. Clin Rheumatol. 2009 Jan. 28(1):79-84. [QxMD MEDLINE Link].
Silva Junior GB, Daher Ede F, Pires Neto Rda J, Pereira ED, Meneses GC, Araújo SM, et al. Leprosy nephropathy: a review of clinical and histopathological features. Rev Inst Med Trop Sao Paulo. 2015 Jan-Feb. 57 (1):15-20. [QxMD MEDLINE Link].
Meena M, Joshi R, Yadav V, et al. Case Report: Lepromatous Leprosy Masquerading as Acute Suppurative Lymphadenitis. Am J Trop Med Hyg. 2023 May 15. [QxMD MEDLINE Link].
Silva EA, Iyer A, Ura S, et al. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health. 2007 Dec. 12(12):1450-8. [QxMD MEDLINE Link].
Parkash O, Kumar A, Pandey R, Nigam A, Girdhar BK. Performance of a lateral flow test for the detection of leprosy patients in India. J Med Microbiol. 2008 Jan. 57:130-2. [QxMD MEDLINE Link].
van Hooij A, Tjon Kon Fat EM, van den Eeden SJF, Wilson L, Batista da Silva M, Salgado CG, et al. Field-friendly serological tests for determination of M. leprae-specific antibodies. Sci Rep. 2017 Aug 21. 7 (1):8868. [QxMD MEDLINE Link].
Parkash O, Kumar A, Pandey R, Franken KL, Ottenhoff TH. Detection of Mycobacterium leprae infection employing a combinatorial approach of anti-45 kDa and modified anti-PGL-I antibody detection assays. J Med Microbiol. 2007 Aug. 56:1129-30. [QxMD MEDLINE Link].
Duthie MS, Balagon MF, Maghanoy A, Orcullo FM, Cang M, Dias RF. Rapid Quantitative Serological Test for Detection of Infection with Mycobacterium leprae, the Causative Agent of Leprosy. J Clin Microbiol. 2014 Feb. 52(2):613-9. [QxMD MEDLINE Link].
Bang PD, Suzuki K, Phuong le T, Chu TM, Ishii N, Khang TH. Evaluation of polymerase chain reaction-based detection of Mycobacterium leprae for the diagnosis of leprosy. J Dermatol. 2009 May. 36(5):269-76. [QxMD MEDLINE Link].
Natrajan M, Katoch K, Katoch VM, Das R, Sharma VD. Histological diagnosis of early and suspicious leprosy by in situ PCR. Indian J Lepr. 2012 Jul-Sep. 84(3):185-94. [QxMD MEDLINE Link].
Phetsuksiri B, Rudeeaneksin J, Supapkul P, Wachapong S, Mahotarn K, Brennan PJ. A simplified reverse transcriptase PCR for rapid detection of Mycobacterium leprae in skin specimens. FEMS Immunol Med Microbiol. 2006 Dec. 48(3):319-28. [QxMD MEDLINE Link].
Duthie MS, Orcullo FM, Abbelana J, Maghanoy A, Balagon MF. Comparative evaluation of antibody detection tests to facilitate the diagnosis of multibacillary leprosy. Appl Microbiol Biotechnol. 2016 Apr. 100 (7):3267-75. [QxMD MEDLINE Link].
Marçal PHF, Fraga LAO, Mattos AMM, Menegati L, Coelho ADCO, Pinheiro RO, et al. Utility of immunoglobulin isotypes against LID-1 and NDO-LID for, particularly IgG1, confirming the diagnosis of multibacillary leprosy. Mem Inst Oswaldo Cruz. 2018. 113 (5):e170467. [QxMD MEDLINE Link].
Reja AH, De A, Biswas S, Chattopadhyay A, Chatterjee G, Bhattacharya B. Use of fine needle aspirate from peripheral nerves of pure-neural leprosy for cytology and PCR to confirm the diagnosis: a pilot study. Indian J Dermatol Venereol Leprol. 2013 Nov-Dec. 79(6):789-94. [QxMD MEDLINE Link].
Ray R, Mondal RK, Pathak S. Diagnosis of erythema nodosum leprosum (type 2 reaction) by cytology. Acta Cytol. 2014. 58(1):29-32. [QxMD MEDLINE Link].
Rothschild BM, Rothschild C. Skeletal manifestations of leprosy: analysis of 137 patients from different clinical settings in the pre- and post-modern treatment eras. J Clin Rheumatol. 2001 Aug. 7(4):228-37. [QxMD MEDLINE Link].
Frade MA, Nogueira-Barbosa MH, Lugão HB, Furini RB, Marques Júnior W, Foss NT. New sonographic measures of peripheral nerves: a tool for the diagnosis of peripheral nerve involvement in leprosy. Mem Inst Oswaldo Cruz. 2013 May. 108(3):[QxMD MEDLINE Link].
Garbino JA, Heise CO, Marques W Jr. Assessing nerves in leprosy. Clin Dermatol. 2016 Jan-Feb. 34 (1):51-8. [QxMD MEDLINE Link].
Gupta SK, Nigam S, Mandal AK, Kumar V. S-100 as a useful auxiliary diagnostic aid in tuberculoid leprosy. J Cutan Pathol. 2006 Jul. 33(7):482-6. [QxMD MEDLINE Link].
Reja AH, Biswas N, Biswas S, Dasgupta S, Chowdhury IH, Banerjee S. Fite-Faraco staining in combination with multiplex polymerase chain reaction: a new approach to leprosy diagnosis. Indian J Dermatol Venereol Leprol. 2013 Sep-Oct. 79(5):693-700. [QxMD MEDLINE Link].
Reddy RR, Singh G, Sacchidanand S, et al. A comparative evaluation of skin and nerve histopathology in single skin lesion leprosy. Indian J Dermatol Venereol Leprol. 2005 Nov-Dec. 71(6):401-5. [QxMD MEDLINE Link].
World Health Organization. WHO Model Prescribing Information: Drugs Used in Leprosy, 1998. Available at http://apps.who.int/medicinedocs/en/d/Jh2988e/5.html.
Health Resources and Services Administration. Recommended Treatment Regimens. US Department of Health and Human Services. Available at https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html. April 2018; Accessed: May 14, 2018.
Cambau E, Saunderson P, Matsuoka M, et al, on behalf of the WHO surveillance network of antimicrobial resistance in leprosy. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. Clin Microbiol Infect. 2018 Mar 1. [QxMD MEDLINE Link].
Sapkota BR, Shrestha K, Pandey B, Walker SL. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. Lepr Rev. 2008 Dec. 79(4):425-8. [QxMD MEDLINE Link].
Balagon MF, Cellona RV, Abalos RM, Gelber RH, Saunderson PR. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy. Lepr Rev. 2010 Mar. 81(1):27-33. [QxMD MEDLINE Link].
Lakshmi C, Srinivas CR. Lepromatous leprosy treated with combined chemotherapy and immunotherapy (injection BCG): three case reports. Int J Dermatol. 2014 Jan. 53(1):61-5. [QxMD MEDLINE Link].
Duthie MS, Hay MN, Rada EM, et al. Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. Eur J Clin Microbiol Infect Dis. 2011 May 5. [QxMD MEDLINE Link].
Jaume L, Hau E, Monsel G, et al. Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study. PLoS Negl Trop Dis. 2023 Apr. 17 (4):e0011238. [QxMD MEDLINE Link]. [Full Text].
Moet FJ, Pahan D, Oskam L, Richardus JH. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. 2008 Apr 5. 336(7647):761-4. [QxMD MEDLINE Link]. [Full Text].
Feenstra SG, Pahan D, Moet FJ, Oskam L, Richardus JH. Patient-related factors predicting the effectiveness of rifampicin chemoprophylaxis in contacts: 6 year follow up of the COLEP cohort in Bangladesh. Lepr Rev. 2012 Sep. 83(3):292-304. [QxMD MEDLINE Link].
Smith WC. Chemoprophylaxis in the prevention of leprosy. BMJ. 2008 Apr 5. 336(7647):730-1. [QxMD MEDLINE Link].
